1. Introduction {#sec1}
===============

Epilepsy is one of the prevalent serious neurological disorders \[[@B1]\] affecting approximately 50 million people worldwide \[[@B2]\].

During the last years, a large variety of antiepileptic drugs (AEDs) with different mechanisms of action were developed, which makes the epilepsy treatment a big challenge \[[@B3]--[@B5]\]. In fact, at least one-third of epileptic patients are or become resistant to treatment and experience recurrent seizures \[[@B6], [@B7]\]. This pharmacoresistance depends on several factors primarily age, epileptic etiology, type, and syndrome, AEDs \[[@B8]\].

Moreover, genetic factors play an important role in the development of refractory epilepsy. Indeed, the prediction of the individual\'s response to AEDs is very helpful for knowing drug resistance mechanisms which will allow the selection of the appropriate type of drug treatment and early epilepsy surgical evaluation. Several studies focused on identifying the potential genetic markers affecting the pharmacoresistance. They provided several genetic variations affecting pharmacokinetics or pharmacodynamics of AEDs in the treatment of epilepsy. These research works also evaluated the association between variations in drug transporter and their target receptor genes and the occurrence of refractory seizures \[[@B9], [@B10]\].

One of the best studied drug transporters is the transmembrane P-glycoprotein (P-gp). This ATP-dependent efflux-pump protein ensuring the transport and elimination of diverse AEDs at the blood-brain barrier (BBB) is expressed in the brain (astrocytes, endothelial cells, and neurons) \[[@B11]--[@B16]\]. P-gp overexpression reduces the AEDs bioavailability in the epileptic cells, which contributes to refractory epilepsy. Some studies suggested that its altered function could be a result of genetic variants especially SNPs located in the *ABCB1* gene \[[@B4], [@B17]--[@B25]\]. The most studied SNPs in this gene are C1236T (rs1128503) in exon 12, G2677T (rs2032582) in exon 21, and C3435T (rs1045642) in exon 26 \[[@B26]--[@B32]\].

The C3435T is commonly considered as a critical SNP in AED resistance \[[@B33]--[@B36]\]. Results of assessing the association of *ABCB1* polymorphisms with the resistance to AEDs are discordant. An initial study reported that patients with drug resistance epilepsy (DRE), compared to AED responders, were more likely to have CC genotype (27.5% vs. 15.7%, respectively) than TT genotype (19.5% vs. 29.6%, respectively) \[[@B37]\]. This finding was confirmed in some studies \[[@B21], [@B27], [@B38], [@B39]\], while others showed an opposite result \[[@B29], [@B40]--[@B42]\]. Likewise, other studies \[[@B6], [@B43]--[@B47]\] and meta-analyses revealed no significant association between genetic profile and refractory epilepsy \[[@B35], [@B48]--[@B53]\]. These conflicting findings are essentially due to heterogeneity, phenotyping and genotyping errors, bias, etc.

Despite the fact that there was a significant interest in showing the associations between drug resistance and *ABCB1* 3435 genotypes, the clinical practice of a *ABCB1* SNPs routine testing to predict the patient\'s response to the therapy has not been yet examined \[[@B32], [@B49], [@B54]\]. Therefore, we focus, in this work, on evaluating the relationship between the *ABCB1* C1236T, G2677T, and C3435T polymorphisms and the pharmacoresistant epilepsy in Tunisian patients.

2. Materials and Methods {#sec2}
========================

2.1. Study Population {#sec2.1}
---------------------

The present study includes 100 Tunisian epileptic patients, originated from north of Tunisia (56 males and 44 females) with a mean age of 6.710 ± 4.358. All epilepsy patients were evaluated in the Neuro-pediatric Department at Mongi Ben Hamida National Institute of Neurology. They were diagnosed for epilepsy after a follow-up of one year or more and treated by AED monotherapy or bitherapy.

This study was conducted in accordance with the ethical standards of the declaration of Helsinki \[[@B55]\]. It was approved by a local human research ethics committee (HTHEC-2016-30). An informed consent was signed by all patients and/or their parents.

All subjects were examined by a qualified epilepsy neurologist and had a confirmed diagnosis based on the operational clinical definition of epilepsy \[[@B8]\] and classified according to the guidelines specified in the International League Against Epilepsy (ILAE) \[[@B56], [@B57]\].

Information on demographic and clinical characteristics were obtained from structured questionnaires and medical records database. The collected information included sex, age, age at seizure onset, family history of epilepsy, types and etiology of seizures, epileptic syndromes, treatment therapy, and the number of prescribed AEDs ([Table 1](#tab1){ref-type="table"}).

### 2.1.1. Definition of Drug Resistance {#sec2.1.1}

According to the definition set by the ILAE, patients were considered as drug-resistant to epilepsy if the adequate trials of two tolerated and appropriately used AED schedules (whether monotherapies or combination) failed to achieve sustained seizure freedom \[[@B58]\].

The nonresponders must not have a lesional pharmacoresistant epilepsy \[[@B42], [@B59], [@B60]\].

All associated pathologies that might promote the occurrence of epileptic seizures and may lead to wrong diagnosis of epilepsy were excluded from this study (imaging abnormalities including tumor, progressive or degenerative neurological or systemic disorders, tuberculoma, multiple neurocysticercosis, vascular malformations, and atrophic lesions; hepatic, renal \[[@B42], [@B59], [@B60]\], gross neurological deficits (mental retardation, motor/speech), diabetes mellitus \[[@B60]\], hematopoietic \[[@B61]\], cardiac insufficiency \[[@B42], [@B62]\]; infectious, traumatic, metabolic, and deep psychiatric disorders \[[@B62]\]; cancers \[[@B42]\] or secondary metastases \[[@B31]\]).

On the other hand, any subject who neglected the treatment regimen or presented any exclusion criteria (verified poor compliance by performing blood tests of MAEs \[[@B63]\]; adverse drug reactions of AEDs \[[@B61]\]; alcohol, addiction \[[@B59]\], or drug intake (inducers or inhibitors of enzymes that metabolize MAEs; substrates or inhibitors of P-gp \[[@B63]\]), was also excluded from this work.

### 2.1.2. Definition of Drug Responsiveness {#sec2.1.2}

The patients were considered as drug-responsive if they did not have any type of seizures for, at least, 1 year during AED treatment \[[@B58], [@B64]\].

In our population, 50 drug-responsive patients constituting "the control group" (males : females = 28 : 22) were matched according to sex, age, and geographic region \[[@B42]\] with 50 drug-resistant patients constituting "the patient group" (males : females = 28 : 22). Refractory and responsive patients were unrelated ([Table 1](#tab1){ref-type="table"}).

2.2. DNA Extraction and Genetic Analysis {#sec2.2}
----------------------------------------

Blood samples (5-10 ml) were collected in ethylenediamine tetraacetic acid (EDTA) tubes from each patient and control. Genomic DNA was isolated from whole blood samples. For all patients and controls, 3 SNPs of *ABCB1* gene (C1236T, G2677T, and C3435T) were genotyped by polymerase chain reaction (PCR) assay using a SimpliAmp™ (Applied Biosystems-Life Technologies) followed by restriction fragment length polymorphism (RFLP) analysis. The fragments were amplified with 0.4 mM dNTPs, 4 mM MgCl2, nuclease-free water, reaction buffer, 20 *μ*mol/l of primers, and 0.05 U Taq polymerase in a final volume of 50 *μ*l using a PCR Master Mix (Thermo Fisher Scientific) using the following program for the 3 SNPs (rs1128503, rs2032582, rs1045642): 94°C for 2 min, 35 cycles (94°C for 30s, 60°C for 30s, 72°C for 30s), and 72°C for 7 min \[[@B65]\] ([Table 2](#tab2){ref-type="table"}).

After amplification, PCR products were digested using 2 *μ*l specific restriction endonucleases (HaeIII, BanI, and Sau3A1 (Thermo Fisher Scientific)), 9.5 *μ*l nuclease-free water, 4.5 *μ*l restriction enzyme buffer, and 4 *μ*l PCR products in a final volume of 20 *μ*l. The separated fragments were visualized on 3% agarose gel after incubation at 37°C for 16 h. The restriction specific sites and sizes of digested fragments are summarized in [Table 3](#tab3){ref-type="table"}.

2.3. Statistical Analysis {#sec2.3}
-------------------------

The chi-square (*X*^2^) test (2 × 2 contingency tables) was performed to compare allelic and genotypic distribution of *ABCB1* C1236T, G2677T, and C3435T polymorphisms between drug-resistant group (patients group) and drug-responsive group (control group). The association is statistically significant when *p*-value is ≤0.05 \[[@B66]\]. The statistical analysis was conducted with logiciel Epi info™ 7 \[[@B67]\].

Linkage disequilibrium (LD) analysis and haplotype construction were carried out by SHEsis online software \[[@B68]\]. The *r*^2^ (correlation index) and *D* (LD coefficient) were calculated, to test the LD among the 3 loci. If *r*^2^ and ∣*D*′∣ = 1, the alleles are in a complete LD (separated by recombination). If *r*^2^ and ∣*D*′∣ \< 1, the LD is disrupted. Associations between allelic, genotype, haplotype, and drug response were estimated by odds ratio (OR) with 95% confidence interval (CI).

3. Results {#sec3}
==========

3.1. Demographics and Clinic Characteristics {#sec3.1}
--------------------------------------------

The sex ratio was predominantly male (56 vs. 44%) with a mean age in years of 6.710 ± 4.358 and a mean age at seizure onset of 3.820 ± 3.362.

For patients group, the mean age was 6.220 ± 4.432 vs. 7.200 ± 4.271 for control one.

The mean age at seizure onset for nonresponders is 2.680 ± 2.470 and 4.960 ± 3.752 for responders.

Overall, the most common seizure type was generalized (75%). Focal and focal to bilateral tonic-clonic seizures were minoritary (20% and 5%, respectively).

In the drug-resistant group, 84% patients presented generalized seizures, 6% focal and 10% focal to bilateral tonic-clonic ones, whereas in the drug-responder group, 66% of patients presented generalized and 34% of focal seizures, but no focal to bilateral tonic-clonic seizures were observed.

The syndromes (such as absences, continuous spikes, and waves during sleep (CSWS), Lennox-Gastaut\...) constituted only 26% of our epileptic patients: 38% in drug-resistant group vs. 14% in drug-responsive group.

The epileptic etiology for the epileptic patients was mainly unknown (57%). The main factor seems to be genetic (48%) for the drug-resistant patients with known etiology, whereas it seems to be a structural one (20%) for the drug-responsive patients.

The medical history observed is low (16%) in epileptic patients, drug responders, and none.

The patients enrolled in this study received mainly a polytherapy AEDs (42%) as well in drug-resistant patients (84%), while for the drug-responsive patients, it was a monotherapy (68%).

3.2. Polymorphisms Analysis and Susceptibility to DRE {#sec3.2}
-----------------------------------------------------

### 3.2.1. Genotypic and Allelic Analysis {#sec3.2.1}

We found a significant allelic and genotypic association between C1236T, G2677T, and C3435T polymorphisms and response to AEDs ([Figure 1](#fig1){ref-type="fig"}). In fact, we observed that the TT genotypes and (*p* ≤ 0.001 for C1236T, *p* = 0.001 for G2677T, *p* ≤ 0.001 for C3435T) the T allele of the 3 SNPs (T vs. C, OR = 3.650, 2.029-6.563, *p* ≤ 0.001 for C1236T; T vs. C, OR = 1.801, 1.016-3.192, *p* = 0.044 for G2677T; T vs. C, OR = 4.730, 2.604-8.591, *p* ≤ 0.001 for C3435T) were significantly more frequent in drug-resistant patients than in drug-responsive patients. The *ABCB1* genotype and allele frequencies are shown in Tables [4](#tab4){ref-type="table"} and [5](#tab5){ref-type="table"}, respectively.

### 3.2.2. Haplotypic Analysis {#sec3.2.2}

The obtained results showed a significant degree of LD between C1236T and G2677T (∣*D*′∣ = 0.211), G2677T and C3435T (∣*D*′∣ = 0.035), and C1236T and C3435T (∣*D*′∣ = 0.236). In fact, the *r*^2^ coefficient between C1236T and G2677T, G2677T and C3435T, and C1236T and C3435T were 0.033, 0.001, and 0.039, respectively.

The ORs of CT and TT haplotypes (C1236T and G2677T); GT, TC, and TT haplotypes (G2677T and C3435T); and CT and TT haplotypes (C1236T and C3435T) were significantly higher in nonresponder patients than in responder patients: 3.500, 1.152-10.633, *p* = 0.027 and 19.056, 2.395-151.604, *p* = 0.005; 3.778, 1.343-10.628, *p* = 0.012, 2.852, 0.995-8.174, *p* = 0.051, and 36.360, 2.095-631.209, *p* = 0.014; 4.929, 1.503-16.158, *p* = 0.009 and 10.286, 2.209-47.902, *p* = 0.003. The more significant OR was observed in TT haplotype for the 3 combinations of SNPs.

Compared to CGC haplotype, ORs of the association between CTT, TGT, TTC, and TTT haplotypes and drug refractory were 17.414, 0.967-313.749, *p* = 0.053; 5.268, 1.077-25.780, *p* = 0.040; 9.333, 1.121-77.707, *p* = 0.039; 18.910, 1.061-337.144, *p* = 0.046, respectively. The most significant effect was noted in TTT haplotype. The distribution of all *ABCB1* haplotypes is represented in Tables [6](#tab6){ref-type="table"}[](#tab7){ref-type="table"}[](#tab8){ref-type="table"}--[9](#tab9){ref-type="table"}.

3.3. Polymorphisms and Patient Data Correlation {#sec3.3}
-----------------------------------------------

We further correlated separately each collected data factor with each genotype, allele, and haplotypes for the studied SNPs (all significant associations are shown in Tables [10](#tab10){ref-type="table"}[](#tab11){ref-type="table"}[](#tab12){ref-type="table"}[](#tab13){ref-type="table"}[](#tab14){ref-type="table"}--[15](#tab15){ref-type="table"}).

### 3.3.1. *ABCB1* Polymorphisms and Gender {#sec3.3.1}

After a gender-based stratification, a significant association between male patients and C1236T, G2677T, and C3435T TT genotypes, C1236T and C3435T T alleles, and TT (G2677T-C3435T) haplotype was observed. We also noted an important association between female patients and G2677T and C3435TTT genotypes ([Table 10](#tab10){ref-type="table"}).

### 3.3.2. *ABCB1* Polymorphisms and Generalized/Focal Epilepsy {#sec3.3.2}

The distribution according to the epileptic etiology led to a significant association between generalized seizures and C1236T, G2677T, and C3435T TT genotypes, C1236T and G2677TT alleles, and TG, TT (C1236T-G2677T), GT, TT (G2677T-C3435T), and TC, TT (C1236T-C3435T) and TGT (C1236T-G2677T-C3435T) haplotypes. In contrast, a significant association was obtained between focal seizures and T allele of C3435T and CT (C1236T-C3435T) haplotype ([Table 11](#tab11){ref-type="table"}).

### 3.3.3. *ABCB1* Polymorphisms and Epileptic Syndromes {#sec3.3.3}

The C1236T, G2677T, and C3435T TT genotypes were considerably higher in nonresponders with epileptic syndromes vs. responders ([Table 12](#tab12){ref-type="table"}).

### 3.3.4. *ABCB1* Polymorphisms and Unknown/Genetic Epileptic Etiology {#sec3.3.4}

Significant associations were noticed between genetic etiology and C1236T, G2677T, and C3435T TT genotypes, C1236T T alleles, and TT (C1236T-G2677T), GT, TT (G2677T-C3435T), and CT, TT (C1236T-C3435T) haplotypes. An association between unknown etiology and G2677T GG, TT genotypes and C3435T T alleles was also observed ([Table 13](#tab13){ref-type="table"}).

### 3.3.5. *ABCB1* Polymorphisms and Medical History {#sec3.3.5}

The association analysis of the *ABCB1* gene revealed that C1236T, G2677T, and C3435T TT genotypes, C1236T T alleles, and TT (C1236T-G2677T) haplotypes were significantly associated with medical history ([Table 14](#tab14){ref-type="table"}).

### 3.3.6. *ABCB1* Polymorphisms and AED Therapy {#sec3.3.6}

We evaluated the association of drug responders and nonresponders with *ABCB1* SNPs according to the individual monotherapy, bitherapy, and polytherapy. We only noted a significant association between bitherapy and G2677T TT genotypes and G2677TT alleles ([Table 15](#tab15){ref-type="table"}).

4. Discussion {#sec4}
=============

The response to medications varies greatly from one individual to another \[[@B69]\]. The term "drug resistance" is a commonly encountered complication in clinical practice. The concept of DRE existed since the intake of AEDs and the failure of treatment (persistence of seizures). It was observed that patients became resistant to most or to all broad range AEDs with different mechanisms of action \[[@B70]\]. The reported frequency of nonresponders is approximately 30% \[[@B4], [@B10], [@B71], [@B72]\].

According to the obtained results, males were more likely to develop DRE in our study population. This results is in accordance with other reported studies \[[@B73]--[@B75]\].

In accordance with epilepsy type, drug-resistant and drug-responsive patients showed a predominance of generalized seizures (84% vs. 66%), compared to focal (6% vs. 34%) and focal to bilateral tonic-clonic seizures (10% vs. 0%). Some studies provided the same results \[[@B74], [@B76], [@B77]\], while many others showed the opposite \[[@B32], [@B73], [@B75], [@B78]--[@B82]\] due to some changes recently made in the classifications of epilepsies taken into account the type of onset seizures \[[@B32], [@B56]\]. Epileptic syndromes represented only 26% of our epileptic patients, in fact that most of our patients with isolated seizures have no EEG results or have an EEG with no specific electroclinical syndrome. This result is similar to another study from the center of Tunisia (18.3%) \[[@B32]\]. The etiology remained unknown in 57% of our cases, in drug-resistant patients and drug-responsive ones (52% and 62%). The same result was observed in the study of Banerjee et al. \[[@B74]\].

Medical history was heterogeneous (not only epileptic seizures but other different types of medical histories) and low for epileptic patients and the 2 other groups. It was also observed that the epilepsy drug resistance was frequent in patients treated with more than two AED molecules (84%), while drug-responsive patients responded more to monotherapy treatment (68%). Ajmi et al. \[[@B32]\] have shown the same results as ours except for the result of the polytherapy because they enrolled in their study only patients treated with first-generation AEDs.

As it was previously indicated, the development of DRE depends on several factors \[[@B70]\] such as the genetic differences between individuals. In previous works, the polymorphisms of the *ABCB1* gene, encoding P-gp, were extensively examined in patients with DRE but with conflicting results.

In the present study, we noted a significant association of *ABCB1* C3435T polymorphism with drug resistance in epilepsy. In fact, epileptic seizure recurrence was higher in nonresponders with TT genotype and T allele in comparison with responders.

These findings corroborate those obtained by some studies showing that TT genotype \[[@B21], [@B29], [@B40], [@B41]\] and T allele \[[@B71], [@B72]\] play an important role in seizure recurrence in drug-resistant patients compared to drug-responsive patients. However, Siddiqui et al. \[[@B37]\] were the first to investigate the association between C3435T polymorphism and refractory epilepsy in 315 Caucasians. They reported that DRE might be genetically determined. In fact, they proved that patients with drug-resistant epilepsy are more likely to have the CC genotype than the TT genotype (OR = 2.66; 95% CI (1.32-5.38), *p* = 0.006). The same results were mentioned in other studies demonstrating a higher percentage of C3435T CC genotype \[[@B33], [@B83]\] and C allele \[[@B84]\] carriers in nonresponders to AEDs. The study of Ajmi et al. \[[@B32]\] from the center of Tunisia found a significant association between CT, TT genotypes, and DRE. On the other hand, several works and meta-analyses could not establish an association between C3435T polymorphism and resistant epilepsy \[[@B30], [@B31], [@B40], [@B45], [@B49], [@B71], [@B85], [@B86]\].

The P-gp is mainly found at BBB and in various normal tissues with excretory functions. It plays a central role in the transport of the planar lipophilic agents (AEDs), whose majority are *ABCB1*gene substrates. Considering the presence of some genetic variations in this gene, *ABCB1* overexpression may lead to prevent AEDs from attaining the sites of action and to have the therapeutic effect.

Even if the common genetic variant C3435T is a silent polymorphism that does not alter the amino acid sequence of P-gp, it may influence the transport and the distribution of AEDs, reducing the levels of AEDs in the brain and leading to refractory epilepsy.

It was hypothesized that the CC genotype is associated with overexpression of P-gp near the epileptogenic brain foci \[[@B37]\]. This overexpression together with other efflux transporters in the cerebrovascular endothelium may cause DRE \[[@B21]\].

On the other hand, other studies demonstrated that TT genotype is crucial in P-gp activity influencing the oral bioavailability at the BBB, which based on the assumption that patients bearing this genotype could be more resistant to treatment than those bearing CC genotype \[[@B37]\]. Similar results implied that T allele ensures the overexpression of *ABCB1* in endothelial cells \[[@B54], [@B70], [@B87]\].

Thereby, the presence of C3435T SNP may lead to a high P-gp expression in endothelium tissues and in neurons of epileptic patients \[[@B18]\], resulting in pharmacoresistant epilepsy which can be treated by surgery \[[@B21], [@B88]\]. However, other studies failed to confirm that C3435T SNP is associated to altered P-gp molecular expression and functional activity \[[@B32]\].

The C1236T polymorphism seems likewise to influence the response to AEDs. In fact, we found a significant association between the C1236T TT genotype or T allele and the resistance to AEDs. Contrariwise, the results in the study of Siddiqui et al. \[[@B37]\] showed that the proportion of CC genotype in nonresponders was significantly higher than that in responders (27.5 and 15.7%, respectively), but the proportion of TT genotype was significantly lower in nonresponders than that in responders (19.5 and 29.6%, respectively).

Li et al. \[[@B89]\] failed to find any association in 6324 drug-responsive vs. 6083 drug-resistant patients. The same results were published by Ajmi et al. \[[@B32]\]. As a silent C1236T SNP, no report has until now investigated its possible effect on P-gb activity \[[@B32]\].

A number of studies showed the relation between the variation of the ABCB1 gene expression and/or the P-gp activities and *ABCB1* G2677T (Ala893Thr) SNP \[[@B18], [@B21], [@B27]\]. Our results demonstrated that the drug-resistant patients are more likely to have the TT genotype than the GG genotype. These findings confirm those presented in the study of Seo et al. \[[@B29]\] showing that the risk of drug resistance was more significant in Japanese patients with the TT genotype than those with the GG genotype. In the study of Ajmi et al. \[[@B32]\], the GT and TT genotypes were present in patients with DRE. However, these results contrast with those obtained in other works. For instance, Sánchez et al. \[[@B90]\] found that the distribution of the GG genotype was more higher in the Caucasian adults drug-resistant than drug-responsive.

In the meta-analysis of Li et al. \[[@B89]\], no association was observed in Asians and Caucasians. Overall, serine/alanine amino acid of the coding polymorphism increases P-gp activity, even so other studies failed to demonstrate this effect on P-gp intracellular location, expression level, and function \[[@B32]\].

The discordant results of all these studies could be explained by \[[@B91], [@B92]\]: The small sizes of the studied populations \[[@B63]\]The heterogeneity in selection criteria for study populations (different used study designs and subject definitions, recurrent epileptic seizures, variation in duration which precedes the identification of drug resistance\...) \[[@B63]\]The variable methodologies applied for phenotyping and genotyping \[[@B63]\]The association between *ABCB1* C3435T polymorphism and AEDs might be not real \[[@B93], [@B94]\]The different ethnicities of patients may be correlated to the modification the P-gp expression. Ajmi et al. \[[@B32]\] reported that the level of expression of the T allele of the most studied SNP *ABCB1* C3435T in DRE varied from one ethnic group to another. Moreover, its lowest frequencies were found in Tunisian (0.2) and Egyptian (0.3) \[[@B95]\] populations compared to the other ethnicities (Chinese and Iranian)The heterogeneity of epilepsy including multiple syndromes with various etiologies \[[@B40], [@B95], [@B96]\]The different other actors, such as age, various epileptic etiologies, and variability in drug response to a large AEDs number, should be taken into account

Indeed, Sánchez et al. \[[@B90]\] found a lower risk associated with *ABCB1* 3435TT or 2677TT genotypes in the subgroup of patients (\>12 years). Nevertheless, drug-resistant and drug-responsive groups had different origins of epilepsy and treatments \[[@B93], [@B94]\]. The most used AEDs were P-gp substrates (phenytoin and phenobarbital) in adults with symptomatic epilepsy (Engel classification). On the other hand, the most employed AED in the patients (\<12 years) with idiopathic epilepsy was a nonsubstrate P-gp (VPA) due to the fact that CBZ and VPA have not been yet reported to be a drug substrates of P-gp \[[@B97]\].

Thus, it becomes necessary to confirm the association between *ABCB1* polymorphisms and the levels of P-gp expression and activity in brain tissue in patients with refractory epilepsy before admitting the role of SNPs in resistance to MAEs \[[@B98]\]. So far, no conclusive evidence of C3435T-dependent P-gp expression at the BBB level has substantiated the relationship between *ABCB1* polymorphisms and the expression levels of *ABCB1* brain mRNA or P-gp proteins in refractory epilepsy \[[@B6], [@B98]--[@B100]\].

Haplotypic analysis indicated that CT and TT haplotypes (C1236T and G2677T) were significantly higher in patients with DRE. The GT, TC, and TT haplotypes (G2677T and C3435T) increased considerably the risk of drug-resistant epilepsy. Only the TT haplotype was shown in 3 other studies \[[@B30], [@B32], [@B39]\]. Nevertheless, no association was observed in other population \[[@B101]\]. The patients with DRE were more likely to have CT and TT haplotypes (C1236T and C3435T), compared to drug-responsive patients.

A significant level LD was observed between the C1236T, G2677T, and C3435T SNPs, indicating that these loci reacted as a complex haplotypic system. The haplotype combination CTT, TGT, TTC, and TTT was significantly associated with poor response, while the haplotype combination of CGC was related to good drug response. However, Siddiqui et al. \[[@B37]\] as well as Zimprich et al. \[[@B27]\] showed that the resistance to AEDs therapy was significantly influenced by the presence of the CGC haplotype in Caucasians.

The haplotypic analysis, in another study, \[[@B28]\] demonstrated that Asians with the CGC, TGC, and TTT haplotypes were more likely to be drug resistant. Other studies failed to report any significant association between haplotypes and DRE \[[@B29], [@B30], [@B102]\]. As an example, a meta-analysis for haplotype that included a total of 26 publications (*n* = 7,831 patients) did not reveal any significant associations between polymorphisms and their haplotypes and the response to AEDs whether in the general population or in ethnic subgroups. In addition, the data available in this meta-analysis did not allow carrying out subgroup analyses by the used types of AEDs or epilepsy \[[@B35]\].

Some major reported factors, such as the complex haplotype system, the low sample size, the clinical and genetic heterogeneity in epilepsy, and the environment \[[@B29], [@B35]\], could explain these contradictory results.

Based on our findings, the importance of *ABCB1* haplotype system was highlighted. Screening for these SNPs, which are in high LD, could be related to a significant decrease in intracellular substrate concentration leading to the P-gp overactivity in the BBB \[[@B89], [@B103]--[@B107]\] and could be a stronger marker. Therefore, the combinations of bi- and triallelic haplotypes should be studied.

As in the most incidence and prevalence studies of epilepsy, the disease is more frequent in male than in female patients \[[@B108]--[@B110]\] due to the fact that the majority of men refuse to marry women with epilepsy, which leads to a strong concealment of the pathology.

Nevertheless, we found significant results in female patients with DRE. Indeed, Sidenvall et al. \[[@B111]\] reported that the incidence of infantile epilepsy was rather raised in girls than in boys.

Another study reported that there is no difference between the two sexes as far as DRE is concerned \[[@B112]\].

We also found an increased frequency of focal epilepsies. The same results were obtained in many other works \[[@B32], [@B78], [@B79], [@B81], [@B82]\]. We observed a more significant predominance of generalized seizures compared to focal seizures, in our study. Opposite findings were found in others which classified patients based on of the previous classification \[[@B74], [@B76], [@B77]\]. It is important to notice that recently some changes were made on the classification of epilepsies which include the beginning of seizures. This update was taken into account for our study.

Epileptic syndromes are determined by clinical context, epileptic symptoms, and EEG abnormalities. We noted a limited frequency of resistant patients with epileptic syndromes (38%) due to the lack of access to the EEG. On the other hand, significant associations were found in genotypes.

Obviously, we found that the unknown etiology was also important, which concords to the study of Banerjee et al. \[[@B74]\], reviewing many studies reporting a preponderance of seizures of unknown cause. In addition, the genetic research has evolved to identify multiple genes and genetic variations in epileptic patients, which in turn has led to very significant results concerning genetic etiology (48%) in our drug-resistant patients.

We also noted a significant association between the DRE and the medical history. Indeed, different medical histories may occur in epileptic patients, which does not necessarily explain the resistance to AEDs. According to Hitiris et al. \[[@B113]\], the risk of developing DRE is more important with stroke history or severe trauma. However, in our study, resistant patients did not have a lesional DRE contrarily to the study of Ajmi et al. \[[@B32]\] where the frequency of structural etiology was more common.

Finally, patients enrolled in our study were resistant to all the different administered AEDs. The stratification by each type of AEDs was useless because it can distort results. Our results showed that only bitherapy seems to be concerned by the association of resistance with genetic biomarkers. The same result was showed in the studies of Ajmi et al. \[[@B32]\] and Kwan and Brodie \[[@B112]\]. They noted that the patients who could be predisposed to refractory epilepsy justify the need of a bitherapy.

5. Conclusion {#sec5}
=============

Epilepsy was intensively studied in a large number of research works that used pharmacogenetics in an attempt to improve the therapeutic response relying on a personalized therapy. We found that *ABCB1* polymorphism increases the risk of developing AED resistance. The obtained findings support in part those provided by previous Tunisian study. The screening for the detection of these polymorphisms may be an effective method to a better therapeutic management of the epilepsy by choosing the best treatment option for each patient and predicting the treatment outcome of the newly diagnosed Tunisian patients before the administration of medication. This will, in the long term, reduce the morbidity among them.
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###### 

General characteristics of the study population.

  Variables                         Epileptic patients (*N* = 100)   Patient group (*N* = 50)   Control group (*N* = 50)                           
  --------------------------------- -------------------------------- -------------------------- -------------------------- ------- ------- ------- ----
  Sex ratio                         Male                             56                         56                         28      56      28      56
  Female                            44                               44                         22                         44      22      44      
                                                                                                                                                   
  Age (years)                       6.710 ± 4.358                    6.220 ± 4.432              7.200 ± 4.271                                      
                                                                                                                                                   
  Age at seizure onset (years)      3.820 ± 3.362                    2.680 ± 2.470              4.960 ± 3.752                                      
                                                                                                                                                   
  Type of seizure                   Generalized                      75                         75                         42      84      33      66
  Focal                             20                               20                         3                          6       17      34      
  Focal to bilateral tonic-clonic   5                                5                          5                          10      0       0       
                                                                                                                                                   
  Epileptic syndrome                Yes                              26                         26                         19^a^   38      7^b^    14
  No                                74                               74                         31                         62      43      86      
                                                                                                                                                   
  Etiology of epilepsy              Autoimmune                       0                          0                          0       0       0       0
  Genetic                           31                               31                         24                         48      7       14      
  Infectious                        1                                1                          0                          0       1       2       
  Metabolic                         1                                1                          0                          0       1       2       
  Structural                        10                               10                         0                          0       10      20      
  Unknown                           57                               57                         26                         52      31      62      
                                                                                                                                                   
  Medical history                   Yes                              16                         16                         8^c^    16      8^d^    16
  No                                84                               84                         42                         84      42      84      
                                                                                                                                                   
  Antiepileptic treatment           Monotherapy                      34                         34                         0       0       34^e^   68
  Bitherapy                         24                               24                         8^f^                       16      16^g^   32      
  Polytherapy                       42                               42                         42^h^                      84      0       0       

Values (*n* and %). ^a^Absences, Angelman, continuous spikes and waves during sleep (CSWS), Dalla Benardina, Doose, Dravet, Ohtahara, early myoclonic encephalopathy (EME), generalized epilepsy with febrile seizures plus (GEFS+), juvenile myoclonic epilepsy (JME), Lennox-Gastaut, WEST. ^b^Absences, benign epilepsy with centro-temporal spikes (BECTS), early myoclonic encephalopathy (EME), idiopathic generalized epilepsies (IGE), tuberous sclerosis of Bourneville (STB). ^c^Appendectomy, bronchopneumopathy, dehydration and gastroenteritis, febrile seizures, mental retardation with behavioral disorder, neonatal cyanosis, *recurrent bilateral otitis media*, recurrent urinary tract infections, varicella ^d^Appendectomy, bilateral hernia, bilateral testicular ectopia, enuresis, febrile seizures, gastroesophageal reflux, trauma, maternal-feotal infection, mumps, neonatal hypoglycemia, strabismus, stunting delay. ^e^Controls were prescribed single AED (carbamazepine or valproic acid). ^f^Patients were prescribed a combination of 2 AEDs (carbamazepine, clonazepam, lamotrigine, phenobarbital, valproic acid, vigabatrin). ^g^Controls were prescribed a combination of 2 AEDs (carbamazepine, clonazepam, phenobarbital, valproic acid). ^h^Patients were prescribed a combination of diverse AEDs (carbamazepine, clobazam, clonazepam, diazepam, ethosuximide, lamotrigine, levetiracetam, phenobarbital, phenytoin, topiramate, valproic acid, vigabatrin).

###### 

Sequences of F and R primers used in the study, *T*~m~, and size of the amplicons for each SNP \[[@B65]\].

  SNP              Exon   Primer F                 Primer R                 Tm (°C)   Amplicon size (bp)
  ---------------- ------ ------------------------ ------------------------ --------- --------------------
  *ABCB1* C1236T   12     TATCCTGTGTCTGTGAATTGCC   CCTGACTCACCACACCAATG     60        366
  *ABCB1* G2677T   21     TGCAGGCTATAGGTTCCAGG     TTTAGTTTGACTCACCTTCCCG   60        224
  *ABCB1* C3435T   26     TGTTTTCAGCTGCTTGATGG     AAGGCATGTATGTTGGCCTC     60        197

F: forward; R: reverse; *T*~*m*~: melting temperature; bp: base pair.

###### 

Size and restriction recognition sites of digested fragments for each SNP \[[@B65]\].

  --------------------------------------------------------------------------------------------------------------------
  SNP                      Enzyme^∗^          Unit size^∗^(U)   Restriction site^∗^   Size of digested fragment (bp)
  ------------------------ ------------------ ----------------- --------------------- --------------------------------
  *ABCB1* C1236T           HaeIII (BsuRI)     3000              5′...GG⬇CC...3′\      Wild type: 269 + 62 + 35
                                                                3′...CC⬆GG...5′       

  Mutated type: 269 + 97                                                              

                                                                                      

  *ABCB1* G2677T           BanI (BshNI)       2000              5′...G⬇GYRCC...3′\    Wild type: 198 + 26
                                                                3′...CCRYG⬆G...5′     

  Mutated type: 224                                                                   

                                                                                      

  *ABCB1* C3435T           Sau3A1 (Bsp143I)   1500              5′...⬇GATC...3′\      Wild type: 158 + 39
                                                                3′...CTAG⬆...5′       

  Mutated type: 197                                                                   
  --------------------------------------------------------------------------------------------------------------------

^∗^ <https://www.thermofisher.com/tn/en/home.html;> U: units; bp: base pair.

###### 

Distribution of *ABCB1* genotypes frequencies in drug-responsive and drug-resistant patients.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  SNP                *ABCB1* genotype   Drug-resistant patients (*N* = 50)   Drug-responsive patients\   ORs   95% CI       *p* value          *X* ^2^                     
                                                                             (*N* = 50)                                                                                    
  ------------------ ------------------ ------------------------------------ --------------------------- ----- ------------ ------------------ -------------- ------------ -------
  *ABCB1* C1236T     CC vs. CT+TT       6                                    12                          17    34           0.265              0.094-0.745    0 .012       6.830

  CT vs. CC+TT       18                 56                                   27                          54    0.479        0.215-1.068        0.072          3.270        

  **TT vs. CC+CT**   26                 52                                   6                           12    **7.944**    **2.872-21.978**   **≤0.001**     **18.380**   

  **TT vs. CC**      26                 52                                   6                           12    **12.278**   **3.393-44.433**   **≤0.001**     **16.740**   

  CT vs. CC          18                 56                                   27                          54    1.889        0.625-5.705        0.260          2.890        

  **TT vs. CT**      26                 52                                   6                           12    **6.500**    **2.231-18.940**   **≤0.001**     **12.990**   

                                                                                                                                                                           

  *ABCB1* G2677T     GG vs. GT+TT       10                                   20                          3     6            3.917              1.008-15.220   0.049        4.330

  GT vs. GG+TT       13                 26                                   41                          82    0.077        0.030-0.201        ≤0.001         31.560       

  **TT vs. GG+GT**   27                 54                                   6                           12    **8.609**    **3.110-23.832**   **≤0.001**     **19.950**   

  TT vs. GG          27                 54                                   6                           12    1.350        0.282-6.453        0.707          0.140        

  GT vs. GG          13                 26                                   41                          82    0.095        0.023-0.399        0.001          12.980       

  **TT vs. GT**      27                 54                                   6                           12    **14.192**   **4.808-41.895**   **0.001**      **27.500**   

                                                                                                                                                                           

  *ABCB1* C3435T     CC vs. CT+TT       11                                   22                          24    48           0.306              0.128-0.729    0.008        7.430

  CT vs. CC+TT       9                  18                                   20                          40    0.329        0.132-0.824        0.018          5.880        

  **TT vs. CC+CT**   30                 60                                   6                           12    **11**       **3.952-30.614**   **≤0.001**     **25**       

  **TT vs. CC**      30                 60                                   6                           12    **10.909**   **3.523-33.782**   **≤0.001**     **19.590**   

  CT vs. CC          9                  18                                   20                          40    0.982        0.339-2.840        0.973          0            

  **TT vs. CT**      30                 60                                   6                           12    **11.111**   **3.422-36.081**   **≤0.001**     **18.300**   
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Values (*n* and %). ORs: odds ratio; 95% CI: confidence interval; significant *p* value ≤ 0.05; *X*^2^: chi-square.

###### 

Distribution of *ABCB1* allele frequencies in drug-responsive and drug-resistant patients.

  SNP              *ABCB1* allele   Drug-resistant patients (*N* = 50) (%)   Drug-responsive patients (*N* = 50) (%)   ORs               95% CI        *p* value   *X* ^2^
  ---------------- ---------------- ---------------------------------------- ----------------------------------------- ----------------- ------------- ----------- ---------
  *ABCB1* C1236T   C                30                                       61                                        0.274             0.152-0.493   ≤0.001      19.380
  **T**            70               39                                       **3.650**                                 **2.029-6.563**   **≤0.001**                
                                                                                                                                                                   
  *ABCB1* G2677T   G                33                                       47                                        0.555             0.313-0.985   0.044       4.080
  **T**            67               53                                       **1.801**                                 **1.016-3.192**   **0.044**                 
                                                                                                                                                                   
  *ABCB1* C3435T   C                31                                       68                                        0.211             0.116-0.384   ≤0.001      27.380
  **T**            69               32                                       **4.730**                                 **2.604-8.591**   **≤0.001**                

Values (*n* and %). ORs: odds ratio; 95% CI: confidence interval; significant *p* value ≤ 0.05; *X*^2^: chi-square.

###### 

Haplotype frequencies of the *ABCB1* C1236T and G2677T polymorphisms in drug-responsive and drug-resistant patients.

  *ABCB1* C1236T-G2677T haplotype   Drug-resistant patients (*N* = 50)   Drug-responsive patients (*N* = 50)   ORs   95% CI   *p* value    *X* ^2^                         
  --------------------------------- ------------------------------------ ------------------------------------- ----- -------- ------------ ------------------- ----------- ------------
  CG                                10                                   20                                    39    78       0.071        0.027-0.185         ≤0.001      33.650
  CT                                14                                   28                                    5     10       **3.500**    **1.152-10.633**    **0.027**   **5.260**
  TG                                12                                   24                                    5     10       2.842        0.919-8.791         0.070       3.470
  TT                                14                                   28                                    1     2        **19.056**   **2.395-151.604**   **0.005**   **10.700**

Values (*n* and %). ORs: odds ratio; 95% CI: confidence interval; significant *p* value ≤ 0.05; *X*^2^: chi-square.

###### 

Haplotype frequencies of the *ABCB1* G2677T and C3435T polymorphisms in drug-responsive and drug-resistant patients.

  *ABCB1* G2677T-C3435T haplotype   Drug-resistant patients (*N* = 50)   Drug-responsive patients (*N* = 50)   ORs   95% CI   *p* value    *X* ^2^                         
  --------------------------------- ------------------------------------ ------------------------------------- ----- -------- ------------ ------------------- ----------- ------------
  GC                                6                                    12                                    38    76       0.043        0.015-0.126         ≤0.001      41.560
  GT                                17                                   34                                    6     12       **3.779**    **1.343-10.628**    **0.019**   **6.830**
  TC                                14                                   28                                    6     12       **2.852**    **0.995-8.174**     **0.051**   **4**
  TT                                13                                   26                                    0     0        **36.360**   **2.095-631.209**   **0.014**   **14.940**

Values (*n* and %). ORs: odds ratio; 95% CI: confidence interval; significant *p* value ≤ 0.05; *X*^2^: chi-square.

###### 

Haplotype frequencies of the *ABCB1* C1236T and C3435T polymorphisms in drug-responsive and drug-resistant patients.

  *ABCB1* C1236T-C3435T haplotype   Drug-resistant patients (*N* = 50)   Drug-responsive patients (*N* = 50)   ORs   95% CI   *p* value    *X* ^2^                        
  --------------------------------- ------------------------------------ ------------------------------------- ----- -------- ------------ ------------------ ----------- ------------
  CC                                9                                    18                                    40    80       0.055        0.020-0.149        ≤0.001      38.460
  CT                                15                                   30                                    4     8        **4.929**    **1.503-16.158**   **0.009**   **7.860**
  TC                                11                                   22                                    4     8        3.244        0.956-11.001       0.059       3.840
  TT                                15                                   30                                    2     4        **10.286**   **2.209-47.902**   **0.003**   **11.980**

Values (*n* and %). ORs: odds ratio; 95% CI: confidence interval; significant *p* value ≤ 0.05; *X*^2^: chi-square.

###### 

Haplotype frequencies of the *ABCB1* C1236T, G2677T, and C3435T polymorphisms in drug-responsive and drug-resistant patients.

  *ABCB1* C1236T-G2677T-C3435T haplotype   Drug-resistant patients (*N* = 50)   Drug-responsive patients (*N* = 50)   ORs   95% CI   *p* value    *X* ^2^                           
  ---------------------------------------- ------------------------------------ ------------------------------------- ----- -------- ------------ --------------------- ----------- -----------
  CGC                                      3                                    6                                     35    70       0.027        0.0073-0.1019         ≤0.001      43.460
  TTC                                      8                                    16                                    1     2        **9.333**    **1.1210-77.7072**    **0.039**   **5.980**
  TGC                                      1                                    2                                     3     6        0.320        0.0321-3.1837         0.331       1.040
  CTT                                      7                                    14                                    0     0        **17.414**   **0.9665-313.7492**   **0.053**   **7.530**
  CGT                                      8                                    16                                    4     8        2.191        0.6145-7.8082         0.227       1.520
  TTT                                      8                                    16                                    0     0        **18.910**   **1.0607-337.1442**   **0.046**   **8.700**
  CTC                                      6                                    12                                    5     10       1.227        0.3490-4.3158         0.750       0.100
  TGT                                      9                                    18                                    2     4        **5.268**    **1.0766-25.7798**    **0.040**   **5.010**

Values (*n* and %). ORs: odds ratio; 95% CI: confidence interval; significant *p* value ≤ 0.05; *X*^2^: chi-square.

###### 

Association of *ABCB1* polymorphisms and drug resistance in male and female epileptic subgroups.

  -------------------------- ------------------------------------ ------------------------------------- -------- -------- ----------- -------------- --------------- -------- --------
  Male                       Drug-resistant patients (*N* = 28)   Drug-responsive patients (*N* = 28)   ORs      95% CI   *p* value   *X* ^2^                                 
  *n*                        \%                                   *n*                                   \%                                                                    
  *ABCB1* C1236T genotypes   TT vs. CC+CT                         16                                    57.143   3        10.714      11.111         2.707-45.613    0.001    13.460
  TT vs. CC                  16                                   84.211                                3        25       16.000      2.654-96.472   0.003           10.870   
  TT vs. CT                  16                                   64                                    3        15.789   9.482       2.160-41.612   0.003           10.230   
  *ABCB1* G2677T genotypes   TT vs. GG+GT                         15                                    53.571   4        14.286      6.923          1.900-25.228    0.003    9.640
  *ABCB1* C3435T genotypes   TT vs. CC+CT                         18                                    64.286   4        14.286      10.800         2.912-40.057    ≤0.001   14.670
  TT vs. CC                  18                                   78.261                                4        22.222   12.600      2.843-55.841   0.001           12.750   
  *ABCB1* C1236T alleles     T vs. C                              41                                    73.214   22       39.286      4.224          1.901-9.386     ≤0.001   13.100
  *ABCB1* C3435T alleles     T vs. C                              41                                    73.214   18       32.143      5.770          2.554-13.037    ≤0.001   18.950
  *ABCB1* G2677T-C3435T      TT                                   7                                     25       0        0           19.884         1.076-367.565   0.045    8
                                                                                                                                                                              
  Female                     Drug-resistant patients (*N* = 22)   Drug-responsive patients (*N* = 22)   ORs      95% CI   *p* value   *X* ^2^                                 
  *n*                        \%                                   *n*                                   \%                                                                    
  *ABCB1* G2677T genotypes   TT vs. GT                            12                                    75       2        9.524       28.500         4.504-180.326   ≤0.001   16.550
  *ABCB1* C3435T genotypes   TT vs. CT                            12                                    75       2        16.667      15.000         2.258-99.643    0.005    9.330
  -------------------------- ------------------------------------ ------------------------------------- -------- -------- ----------- -------------- --------------- -------- --------

Values (*n* and %). ORs: odds ratio; 95% CI: confidence interval; significant *p* value ≤ 0.05; *X*^2^: chi-square.

###### 

Association of *ABCB1* polymorphisms and drug resistance in generalized and focal epileptic subgroups.

  -------------------------- ------------------------------------ ------------------------------------- -------- -------- ----------- --------------- --------------- -------- --------
  Generalized                Drug-resistant patients (*N* = 42)   Drug-responsive patients (*N* = 33)   ORs      95% CI   *p* value   *X* ^2^                                  
  *n*                        \%                                   *n*                                   \%                                                                     
  *ABCB1* C1236T genotypes   TT vs. CC+CT                         23                                    54.762   2        6.061       18.763          3.968-88.729    ≤0.001   19.720
  TT vs. CC                  23                                   82.143                                2        14.286   27.600      4.644-164.027   ≤0.001          17.840   
  *ABCB1* G2677T genotypes   TT vs. GG+GT                         24                                    57.143   4        12.121      7.250           2.209-23.800    0.001    12.410
  TT vs. GT                  24                                   68.571                                4        12.903   14.727      4.137-52.423    ≤0.001          20.860   
  *ABCB1* C3435T genotypes   TT vs. CC+CT                         26                                    61.905   3        9.091       16.250          4.254-62.079    ≤0.001   21.740
  TT vs. CC                  26                                   72.222                                3        16.667   13.000      3.086-54.773    0.001           14.900   
  TT vs. CT                  26                                   81.250                                3        16.667   21.667      4.717-99.530    ≤0.001          19.720   
  *ABCB1* C1236T alleles     TT vs. CT                            23                                    61.162   2        9.524       15.607          3.147-77.409    0.001    15.140
  T vs. C                    60                                   71.429                                23       34.848   4.674       2.337-9.348     ≤0.001          20.010   
  *ABCB1* G2677T alleles     T vs. G                              59                                    70.238   35       53.030      2.090           1.067-4.096     0.032    4.680
  *ABCB1* C1236T-G2677T      TG                                   9                                     21.429   1        3.030       8.727           1.045-72.888    0.045    5.410
  TT                         14                                   33.333                                1        3.030    16.000      1.977-129.518   0.009           10.610   
  *ABCB1* G2677T-C3435T      GT                                   13                                    30.952   3        9.091       4.483           1.156-17.382    0.030    5.260
  TT                         12                                   28.571                                0        0        27.459      1.559-483.811   0.024           11.220   
  *ABCB1* C1236T-C3435T      TC                                   10                                    23.810   2        6.061       4.844           0.981-23.908    0.053    4.330
  TT                         13                                   30.952                                0        0        30.661      1.746-538.489   0.019           12.360   
                                                                                                                                                                               
  Focal                      Drug-resistant patients (*N* = 3)    Drug-responsive patients (*N* = 17)   ORs      95% CI   *p* value   *X* ^2^                                  
  *n*                        \%                                   *n*                                   \%                                                                     
  *ABCB1* C3435T alleles     T vs. C                              5                                     83.333   11       32.353      10.455          1.087-100.599   0.042    5.520
  *ABCB1* C1236T-C3435T      CT                                   2                                     66.667   1        5.882       32.000          1.389-737.501   0.030    7.390
  -------------------------- ------------------------------------ ------------------------------------- -------- -------- ----------- --------------- --------------- -------- --------

Values (*n* and %). ORs: odds ratio; 95% CI: confidence interval; significant *p* value ≤ 0.05; *X*^2^: chi-square.

###### 

Association of *ABCB1* polymorphisms and drug resistance in epileptic syndrome subgroups.

  Presence of syndrome       Drug-resistant patients (*N* = 19)   Drug-responsive patients (*N* = 7)   ORs      95% CI   *p* value   *X* ^2^                                 
  -------------------------- ------------------------------------ ------------------------------------ -------- -------- ----------- --------------- --------------- ------- -------
  *ABCB1* C1236T genotypes   TT vs. CC+CT                         11                                   57.895   0        0           20.294          1.014-406.357   0.049   7.020
  TT vs. CT                  11                                   69.750                               0        0        27.182      1.286-574.353   0.034           8.250   
  *ABCB1* G2677T genotypes   TT vs. GT                            9                                    64.286   0        0           22.455          1.051-479.955   0.046   7.010
  *ABCB1* C3435T genotypes   TT vs. CT                            11                                   91.667   1        20          44.000          2.193-882.709   0.013   8.730

Values (*n* and %). ORs: odds ratio; 95% CI: confidence interval; significant *p* value ≤ 0.05; *X*^2^: chi-square.

###### 

Association of *ABCB1* polymorphisms and drug resistance in unknown and genetic epileptic subgroups.

  -------------------------- ------------------------------------ ------------------------------------- -------- -------- ----------- ---------------- --------------- -------- --------
  Genetic                    Drug-resistant patients (*N* = 24)   Drug-responsive patients (*N* = 7)    ORs      95% CI   *p* value   *X* ^2^                                   
  *n*                        \%                                   *n*                                   \%                                                                      
  *ABCB1* C1236T genotypes   TT vs. CC+CT                         14                                    58.333   0        0           20.714           1.062-404.123   0.046    7.450
  TT vs. CT                  14                                   70                                    0        0        24.539      1.175-512.647    0.039           7.950    
  *ABCB1* G2677T genotypes   TT vs. GT                            12                                    60       0        0           19.118           0.947-386.136   0.054    6.690
  *ABCB1* C3435T genotypes   TT vs. CC+CT                         16                                    66.667   1        14.286      12.000           1.226-117.417   0.033    6
  TT vs. CT                  16                                   100                                   1        20       99.000      3.418-2867.633   0.008           15.810   
  *ABCB1* C1236T alleles     T vs. C                              33                                    68.750   5        35.714      3.960            1.132-13.850    0.031    4.990
                                                                                                                                                                                
  Unknown                    Drug-resistant patients (*N* = 26)   Drug-responsive patients (*N* = 31)   ORs      95% CI   *p* value   *X* ^2^                                   
  *n*                        \%                                   *n*                                   \%                                                                      
  *ABCB1* G2677T genotypes   GG vs. GT+TT                         6                                     23.077   1        3.226       9.000            1.006-80.525    0.049    5.170
  TT vs. GG+GT               15                                   57.692                                5        16.129   7.091       2.066-24.344     0.002           10.730   
  *ABCB1* C3435T genotypes   TT vs. CC                            14                                    82.353   3        16.667      23.333           4.021-135.391   ≤0.001   15.100
  *ABCB1* C3435T alleles     T vs. C                              37                                    71.154   19       30.645      5.583            2.491-12.513    ≤0.001   18.570
  *ABCB1* C1236T-G2677T      TT                                   6                                     23.077   1        3.226       9.000            1.006-80.525    0.049    5.170
  *ABCB1* G2677T-C3435T      TT                                   6                                     23.077   0        0           19.976           1.067-374.011   0.045    8
  *ABCB1* C1236T-C3435T      CT                                   8                                     30.769   2        6.452       6.444            1.229-33.805    0.028    5.780
  TT                         6                                    23.077                                1        3.226    9.000       1.006-80.525     0.049           5.170    
  -------------------------- ------------------------------------ ------------------------------------- -------- -------- ----------- ---------------- --------------- -------- --------

Values (*n* and %). ORs: odds ratio; 95% CI: confidence interval; significant *p* value ≤ 0.05; *X*^2^: chi-square.

###### 

Association of *ABCB1* polymorphisms and drug resistance in medical history subgroups.

  Presence of medical history   Drug-resistant patients (*N* = 10)   Drug-responsive patients (*N* = 11)   ORs   95% CI   *p* value   *X* ^2^                                  
  ----------------------------- ------------------------------------ ------------------------------------- ----- -------- ----------- ---------------- --------------- ------- -------
  *ABCB1* C1236T genotypes      TT vs. CC+CT                         6                                     60    1        9.090       15.000           1.342-167.645   0.028   6.110
  TT vs. CC                     6                                    100                                   1     20       39.000      1.277-1190.913   0.036           7.540   
  *ABCB1* G2677T genotypes      TT vs. GG+GT                         6                                     60    1        9.090       15.000           1.342-167.645   0.028   6.110
  TT vs. GT                     6                                    66.667                                1     10       18.000      1.496-216.630    0.023           6.540   
  *ABCB1* C3435T genotypes      TT vs. CC+CT                         6                                     60    1        9.090       15.000           1.342-167.645   0.028   6.110
  TT vs. CT                     6                                    85.714                                1     12.5     42.000      2.136-825.760    0.014           8.040   
  *ABCB1* C1236T alleles        T vs. C                              16                                    80    8        36.364      7.000            1.729-28.337    0.006   8.150
  *ABCB1* C1236T-G2677T         TT                                   5                                     50    0        0           23.000           1.070-494.601   0.045   7.220

Values (*n* and %). ORs: odds ratio; 95% CI: confidence interval; significant *p* value ≤ 0.05; *X*^2^: chi-square.

###### 

Association of *ABCB1* polymorphisms and drug resistance in epileptic patients with AEDs bitherapy subgroups.

  AEDs bitherapy             Drug-resistant patients (*N* = 8)   Drug-responsive patients (*N* = 16)   ORs      95% CI   *p* value   *X* ^2^                                 
  -------------------------- ----------------------------------- ------------------------------------- -------- -------- ----------- --------------- --------------- ------- -------
  *ABCB1* G2677T genotypes   TT vs. GG+GT                        6                                     75       2        12.500      21.000          2.372-185.937   0.006   9.380
  TT vs. GT                  6                                   75                                    2        12.500   21.000      2.372-185.937   0.006           9.380   
  *ABCB1* G2677T alleles     T vs. G                             14                                    87.500   18       56.250      5.444           1.058-28.011    0.043   4.690

Values (*n* and %). ORs: odds ratio; 95% CI: confidence interval; significant *p* value ≤ 0.05; *X*^2^: chi-square.

[^1]: Academic Editor: Donald H. Chace
